Turkish Journal of Nephrology
Original Article

De-Novo anti-HLA Antibodies After Renal Transplantation: Prevalance and Risk Factors


Ankara Üniversitesi Tıp Fakültesi, Nefroloji Bilim Dalı, Ankara, Türkiye


Ankara Üniversitesi Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Ankara, Türkiye


Ankara Üniversitesi Tıp Fakültesi, Klinik İmmünoloji Bilim Dalı, Ankara, Türkiye

Turkish J Nephrol 2011; 20: 77-82
DOI: 10.5262/tndt.2011.1001.13
Read: 707 Downloads: 527 Published: 06 February 2019

AIM: Development of de-novo anti-HLA antibodies in the post-transplant period might be the earliest finding of later chronic antibody mediated rejection. In this study, we aimed to investigate the incidence and risk factors of de-novo anti-HLA antibodies in our kidney allograft recipients.

MATERIAL and METHODS: After exclusion, 91 (64M/27F) patients having functional graft and negative HLA antibody before the transplantation were taken into the analysis. Anti-HLA antibodies were evaluated by the Luminex method.

RESULTS: Duration of posttransplantation time was 38±31 months and the mean age was 38±10. Mean estimated glomerular filtration rate (GFR) was 68±19 ml/min, and the biopsy proven acute rejection rate was 15.2 %. Anti- HLA antibody was observed in 12 patients (13.1%). When the anti-HLA antibody positive group was compared with the negative group, estimated GFR (58±26 ml/min vs. 69±18 ml/ min, (p=0.05)), living donor/cadaveric donor (5/7 vs. 66/13 (p=0.004)), and acute rejection (6/12 (%50) vs. 8/79 (%10.1) (p=0.002)) were significantly different between the groups. Deceased donor and acute rejection were independent risk factors for development of anti-HLA antibody (p=0.008 and p= 0.004, respectively) on multivariate analysis.

CONCLUSION: In conclusion, anti-HLA antibody can be seen after renal transplantation even in stable patients. Acute rejection and deceased donor transplantation are the major risk factors for development of anti-HLA antibodies. 

EISSN 2667-4440